The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma.
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Innovent Biologics; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Provectus; QBiotics; Regeneron
 
Alexander M. Eggermont
Stock and Other Ownership Interests - IO Biotech; Sairopa; Skyline Diagnostics
Honoraria - Agenus; BIOINVENT; BioNTech; Brenus Pharma; CatalYm; Clover Health; Ellipses Pharma; EPICS; Galecto; GenOway; IO Biotech; IQVIA; ISA Pharmaceuticals; Merck; MSD; Pfizer; Pierre Fabre; Sairopa; Scorpion Therapeutics; Sellas Life Sciences; Skyline Diagnostics; TigaTx; Trained Therapeutix Discovery
Consulting or Advisory Role - Agenus; BIOINVENT; BioInvent; Brenus Pharma; CatalYm; Ellipses Pharma; EPICS; GenOway; IO BIOTECH; IO Biotech; IQVIA; ISA Pharmaceuticals; Merck; MSD; Pfizer; Pierre Fabre; Sairopa; Scorpion Therapeutics; Sellas Life Sciences; Skyline Diagnostics; TigaTx; Trained Therapeutix Discovery
Speakers' Bureau - Bristol-Myers Squibb.; Merck; MSD
 
Jeffrey E. Gershenwald
Consulting or Advisory Role - Merck
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Japan; Erasca, Inc; immatics; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pamgene; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sanofi/Regeneron; Seagen; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Erasca, Inc; immatics; Immunocore; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre; Replimune; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Paolo Antonio Ascierto
Consulting or Advisory Role - 4SC; AstraZeneca; Bayer; Bio-AI Health; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Ultimovacs; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bio-AI Health; Pfizer; Replimune
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Philogen; Regeneron; Replimune; Roche; Sanofi/Aventis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Immunocore; IO Biotech; Merck Serono; Merck Sharp & Dohme; Novartis; Philogen; Regeneron; Replimune; Roche; Sanofi/Aventis
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Regeneron; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Sanofi/Aventis
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; IDEAYA Biosciences; Merck Serono; MSD; Nektar; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Roche; Sanofi
 
Antoni Ribas
Leadership - Arcus Biosciences; Lutris; PACT Pharma
Stock and Other Ownership Interests - 4c Biomed; Advaxis; Appia Bio; Arcus Biosciences; Compugen; CytomX Therapeutics; Highlight Therapeutics; ImaginAb; ImmPACT-Bio; Inspirna; Isoplexis; Kite/Gilead; Lutris; MapKure; Merus; PACT Pharma; Pluto Immunotherapeutics; RAPT Therapeutics; Synthekine; Tango Therapeutics
Honoraria - Amgen; AstraZeneca; Chugai/Roche; Genentech/Roche; Merck Sharp & Dohme; Novartis; Sanofi; Vedanta Biosciences
Consulting or Advisory Role - Amgen; Chugai Pharma; Merck; Novartis; Sanofi
Research Funding - Agilent (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Non-viral gene editing to Arsenal Bio
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Novartis (Inst); Phio Pharmaceuticals (Inst)
 
Richard A. Scolyer
Employment - Royal Prince Alfred Hospital
Honoraria - GlaxoSmithKline; Harvard Medical School; Wake Forest School of Medicine
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb GesmbH (Austria); Bristol-Myers Squibb SA (Switzerland); Evaxion Biotech; GlaxoSmithKline; Merck Sharp & Dohme; metaoptima; MSD Sharp & Dohme (Australia) Pty Limited; Myriad Genetics; NeraCare GmbH; Novartis; Novartis; Novartis; Novartis; Provectus Biopharmaceuticals; QBiotics; Roche
Research Funding - Melanoma Research Alliance (MRA); National Health and Medical Research Council; National Health and Medical Research Council; National Health and Medical Research Council; The Ainsworth Foundation (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
(OPTIONAL) Uncompensated Relationships - Melanoma Institute Australia
 
Vernon K. Sondak
Consulting or Advisory Role - Alkermes; Bristol-Myers Squibb; Genesis Drug Discovery & Development; Iovance Biotherapeutics; Merck/Schering Plough; Novartis; Regeneron; Ultimovacs
Research Funding - Neogene Therapeutics (Inst); Skyline Diagnostics (Inst); Turnstone Bio (Inst)
 
Jonathan E Cohen
Consulting or Advisory Role - Novartis
Speakers' Bureau - Bristol-Myers Squibb; Medison; Merck; Roche; Sanofi
Travel, Accommodations, Expenses - Medison; Roche
 
Jinchun Zhang
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (Inst); Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (Inst)
 
Dmitri O. Grebennik
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Clemens Krepler
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; NeoTX; NeoTX; Onc.AI; Pyxis; STipe Therapeutics; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alnylam; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Codiak Biosciences; Crown Bioscience; CStone Pharmaceuticals; Day One Therapeutics; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; Hotspot Therapeutics; Immunocore; Incyte; Inzen Therapeutics; Janssen; Kadmon; KSQ Therapeutics; Merck; Nektar; Novartis; Onc.AI; Partner Therapeutics; Pfizer; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; SERVIER; Silicon Therapeutics; STINGthera; STipe Therapeutics; Synlogic; Synthekine; Tempest Therapeutics; Tesaro; TRex Bio; Werewolf Therapeutics; Xencor; Xilio Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Fstar (Inst); Genmab (Inst); Ikena Oncology (Inst); Immatics (Inst); Incyte (Inst); Kadmon (Inst); KAHR Medical (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); NextCure (Inst); Numab (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Scholar Rock (Inst); Spring bank (Inst); Synlogic (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Trishula Therapeutics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics